0
0
Read Time:8 Minute, 12 Second
The Newborn Screening Market is expected to grow at a CAGR of 7.9% from 2023 to 2030 to reach $2.49 billion by 2030. The growth of this market is mainly driven by the rising prevalence of congenital heart diseases and genetic disorders, the increasing neonatal population, and the rising awareness regarding newborn screening. However, the shortage of healthcare professionals and the emergence of non-invasive prenatal screening technologies restrain the growth of this market. The government programs & legislation promoting newborn screening and emerging economies are expected to create market growth opportunities. However, ethical concerns related to newborn screening and the high costs of genomic newborn testing are major challenges for the market’s growth.
Here are the top 10 companies operating in the Newborn Screening Market
Thermo Fisher Scientific Inc. (U.S.)
Founded in 1956 and headquartered in Massachusetts, U.S., Thermo Fisher offers products and services in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, government, and academic sectors. The company operates through four segments, namely, Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The company operates in the newborn screening market through the Life Sciences Solutions segment.
Thermo Fisher has a strong geographic presence across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa through its subsidiaries, R&D sites, and a strong distribution network. As of December 2022, the company had a headcount of 130,000 employees, of which 67,000 were employed in the Americas, 20,000 in Asia-Pacific, and 42,000 in Europe and the Middle East & Africa.
ARCHIMED Group (France)
Founded in 2014 and headquartered in Lyon, France, ARCHIMED Group is a global investment firm that helps provide internalization, capacity increase, product portfolio, expansions, and acquisitions. The company focuses on small-cap and mid-cap buyout transactions with companies operating in the targeted sections of the healthcare industry, such as Biopharma Products, Consumer Health, Healthcare IT, In Vitro Diagnostics, Life Science Tools & Biologic Services, MedTech, and Pharma Services.
In June 2022, the company acquired Natus Medical Incorporated, a manufacturer and provider of medical devices and solutions focusing on diagnosing and treating sensory and nervous system disorders in newborns.
The company has over 140 members with varied backgrounds, including operational, medical, scientific, and financial professionals. They have offices in North America, Europe, Asia-Pacific, and Latin America. Groupe CARSO (France), DIESSE Diagnostica Senese S.p.A. (Italy), and ZytoMax GmbH (Germany) are some of the companies managed by the ARCHIMED Group that offer products for the newborn screening market.
Founded in 1937 and headquartered in Massachusetts, U.S., PerkinElmer, Inc. is a multinational company that offers products, solutions, and services for the life sciences, diagnostics, and applied markets. It operates through two reportable segments: Discovery & Analytical Solutions and Diagnostics. The company operates in the newborn screening market through the Diagnostics business segment. This segment provides instruments, reagents, and assay platforms to medical labs, hospitals, clinicians, and medical research professionals.
In May 2023, PerkinElmer, Inc. rebranded its life science and diagnostics businesses as Revvity.
The company’s manufacturing and R&D facilities are in several countries, including the U.S., China, Japan, and Germany. Furthermore, the company has a strong network of sales and marketing channels and service personnel in over 38 countries and sells its products and services in over 190 countries.
PerkinElmer sells its products and services predominantly through its distributors. Some of its subsidiaries are PerkinElmer Genetics, Inc. (U.S.), PerkinElmer Pty. Ltd. (Australia), PerkinElmer do Brasil Ltda. (Brazil), PerkinElmer Instruments (Shanghai) Co. Ltd. (China), PerkinElmer SAS (France), PerkinElmer Technologies GmbH & Co. KG (Germany), PerkinElmer Srl (Italy), and PerkinElmer (India) Pvt Ltd. (India).
Medtronic plc (Ireland)
Founded in 1949 and headquartered in Dublin, Ireland, Medtronic plc is a healthcare technology company providing services to healthcare systems, physicians, clinicians, and patients. It researches, designs, manufactures, and sells biomedical engineering products that help alleviate pain, restore health, and extend life.
The company operates in four reportable segments: Cardiovascular Portfolio, Medical Surgical Portfolio, Neuroscience Portfolio, and the Diabetes Operating Unit. The company operates in the newborn screening market through the Medical Surgical Portfolio segment. This segment is divided into Surgical Innovations and Respiratory, Gastrointestinal & Renal Divisions.
Trivitron Healthcare Pvt Ltd. (India)
Founded in 1997 and headquartered in Tamil Nadu, India, Trivitron Healthcare Pvt Ltd. Is a medical technology company that manufactures and distributes medical technology products in the fields of In-Vitro Diagnostics, Imaging & Radiology, Radiation Protection, Newborn Screening, Critical Care & ICU Solutions, and Renal Care Portfolio.
The company sells its products to hospitals, individual healthcare providers, independent clinics and laboratories, extended care facilities, and renal care centers. They have over 2500 employees at present, 25 offices, and 1200+ channel partners. The company has a global presence in over 180 countries, with certified manufacturing facilities in India, the U.S., Finland, Turkey, and China. They also serve more than 10,000 customers.
Meticulous Research in its latest publication on Newborn Screening Market has predicted the growth of 7.9% during the forecast year 2023-2030.
Bio-Rad Laboratories, Inc. (U.S.)
Founded in 1952 and headquartered in California, U.S., Bio-Rad Laboratories, Inc. is a distributor and manufacturer of clinical diagnostics products and life science research. The company supplies and produces various systems and products for healthcare, analytical chemistry, and life science research. Bio-Rad Laboratories operates through reportable segments, namely, Clinical Diagnostics and Life Sciences. The company operates in the newborn screening market through the Clinical Diagnostics segment.
The company has a direct distribution source in over 35 countries outside the U.S., including Afghanistan, France, Hong Kong, Japan, Korea, Iceland, Germany, Australia, Spain, the Netherlands, and South Africa. Some of the major subsidiaries include Bio-Rad Laboratories Pty. Limited (Australia), Bio-Rad Pacific Limited (U.S.), Bio-Rad Laboratories SAS (France), Bio-Rad Laboratories GmbH (Germany), Bio-Rad Laboratories K.K. (Japan), Bio-Rad Korea Limited (Korea), and Bio-Rad China Ltd. (Hong Kong).
Founded in 1904 and headquartered in Hovedstaden, Germany, Demant A/S is a hearing healthcare and audio technology group that provides hearing care and diagnoses for hearing disorders. The company provides hearing implants, diagnostic equipment, and audio solutions to improve people’s hearing. The company operates in two business segments: Hearing Healthcare and Communications. The company operates in the newborn screening market through the Hearing Healthcare segment. The Hearing Healthcare segment is divided into Hearing-Care, Hearing Aids, and Diagnostics.
The company sells its products across 130 countries and has subsidiaries in around 30 countries. Some of the subsidiaries of the company include Oticon (Denmark), Grason-Stadler, Inc. (U.S.), MAICO Diagnostic GmbH (Germany), Oticon Australia Pty. Limited (Australia), and Hidden Hearing International plc (U.K.), among others.
Baebies, Inc. (U.S.)
Founded in 2014 and headquartered in North Carolina, U.S., Baebies, Inc. is a medical technology company that uses digital microfluidics (DMF) to commercialize products and services that provide early disease detection and comprehensive diagnostic solutions. The company provides technology that operates with microfluidics to maximize the diagnostic yield obtained from small volumes of samples of blood. This blood is used to quantitatively measure lysosomal enzyme activity from the dried blood spot specimens of newborns, enabling multifunctional diagnostic testing.
The company offers products and services for newborn and pediatric screening and testing using platforms such as Baebies FINDER and SEEKER systems.
Founded in 2001 and headquartered in Liège, Belgium, ZenTech s.a. is a biotechnology company that diagnoses pathologies that arise in the early life stages. They specialize in In Vitro Diagnostics (IVD) and Radio Isotopic Assays (RIA) for prenatal, neonatal, and pediatric use, using non-invasive techniques. The tests manufactured by the company are non-invasive to screen rare, genetic, chronic, or infectious metabolic diseases in body fluid samples. To meet the growing demands of newborn screening laboratories, ZenTech also provides mass spectrometry and qPCR solutions, along with the company’s immunoenzymatic methods and rapid tests.
The company’s products are sold directly or through distributors and OEM agreements worldwide.
Hoffmann-La Roche Ltd (Switzerland)
Founded in 1896 and headquartered in Basel, Switzerland, F. Hoffmann-La Roche AG is a company dealing in pharmaceuticals and diagnostics. They have differentiated medicines for oncology, immunology, infectious disease, ophthalmology, and central nervous system diseases. They also provide in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management.
Roche’s operating segments are organized into two divisions: Pharmaceuticals and Diagnostics. These two segments are divided into sub-segments. The Pharmaceuticals is further segmented into Roche Pharmaceuticals and Chugai, and the Diagnostics segment is divided into the Core Lab, Molecular Lab, Point of Care, Pathology Lab, and Diabetes Care sub-segments. The company operates in the newborn screening market through the Diagnostics segment and further through the Molecular Lab segment.
The company has a presence worldwide across the Americas, Europe, Africa, Asia, and Oceania. The company has 33 research and development sites and 20 manufacturing sites worldwide in the Pharmaceuticals and Diagnostics segments. Some of the company’s subsidiaries include Roche Diabetes Care Austria GmbH (Austria), Roche Diabetes Care Brasil Ltda. (Brazil), Hoffmann-La Roche Limited (Canada), Roche Diagnostics [Hongkong] Limited (China), Roche Pharmaceuticals A/S (Denmark), Roche Diabetes Care France SAS (France), Roche Diabetes Care Deutschland GmbH (Germany), and Roche Diabetes Care India Private Limited (India).
Authoritative Research on the Newborn Screening Market – Global Opportunity Analysis and Industry Forecast (2023-2030)
Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:
- Recent financial performance
- Key products
- Significant company strategies
- Partnerships and acquisitions
The Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
